Summer Sale
50% off Premium Yearly
NASDAQ:DXCM
Dexcom (DXCM)
Financials 
Technical Analysis 
Aug 27, 2026, 12:00 amThis summary was created by AI, based on 5 opinions in the last 12 months.
Dexcom (DXCM) has recently experienced a notable uptick, rallying 23.9% last month amidst a broader recovery in the Medtech sector. Analysts observed a promising earnings report last week, highlighting a growth trajectory driven by increasing demand for continuous glucose monitoring systems, particularly among diabetic and pre-diabetic patients. Despite these positive indicators, there are concerns regarding a high price-to-earnings (PE) ratio, with some experts suggesting caution and recommending stop-loss measures to mitigate risks. As diabetes remains a pressing health issue, the company is well-positioned for long-term growth. With strong revenue growth exceeding 20% and impressive cash reserves, there is considerable upside potential, although some valuations may appear inflated at present.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
Premium contentPremium contentWe reiterate DXCM as a TOP PICK. The manufacture of continuous glucose monitors sees plenty of growth opportunity ahead for diabetic patients using GLP-1 medicines to monitor blood sugar levels along with those pre-diabetic patients using an over-the-counter monitoring device trying to avoid the disease. Recently reported earnings showed a 22% growth in revenues and free cash flow has doubled over the last two years to exceed $1 billion. We recommend trailing up the stop (from $49) to $56, looking to achieve $86 -- upside potential of 22%. Yield 0%
(Analysts’ price target is $86.42)Premium contentDXCM is the leading maker of continuous glucose monitoring systems in the US. With diabetes being the fastest growing health issue, and only 1% of those affected having access to this type of monitoring, they have a long, long runway for growth. They have developed devices for the larger Type 2 (non-insulin using) group and has been very successful at securing insurance company inclusion. Recently reported revenue growth exceeded 20% and cash reserves are growing, while the company buys back shares. It trades at a heady 35x earnings, but the 30% ROE demonstrates its strong market dominance. We recommend setting a stop-loss at $49, looking to achieve $85 -- upside potential of 32%. Yield 0%
(Analysts’ price target is $85.35)DXCM has been hit hard as investors fear new success of weight loss drugs will reduce demand for diabetes monitoring products. DXCM is not alone in the decline. But it is still growing, and recent comments by analysts suggest the sell off is quite overdone. It has new products on tap and is strong financially. Market share remains robust. Best Buy has started selling its products (not material on its own, but shows an expanding footprint). We would see DXCM as worth holding. Because it is 33X as large was WELL, they are hard to compare. WELL, being smaller, could potentially rise more, but comes with much more overall risk. From a safety and valuation standpoint, we would, today, prefer DXCM.
Unlock Premium - Try 5i Free
- «
- ‹
- 1
- ›
- »
Popular Articles
Dexcom (DXCM) Frequently Asked Questions
What is Dexcom stock symbol?
Dexcom is a American stock, trading under the symbol DXCM (previously DXCM-Q on Stockchase) on the NASDAQ (DXCM). It is usually referred to as NASDAQ:DXCM or DXCM
Is Dexcom a buy or a sell?
In the last year, 5 stock analysts issued a Buy, Sell, or Hold rating on DXCM (previously DXCM-Q on Stockchase). 5 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is WEAK BUY. Read the latest stock experts' ratings for Dexcom.
Is Dexcom a good investment or a top pick?
Dexcom was recommended as a Top Pick by Jim Cramer - Mad Money on 2026-08-03. Read the latest stock experts ratings for Dexcom.
Why is Dexcom stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Dexcom.
Is Dexcom worth watching?
Dexcom is followed by 23 investors on Stockchase and is a trending stock that is worth watching.
What is Dexcom stock price?
On 2026-08-26, Dexcom (DXCM) stock closed at a price of $88.96.
'%20fill='%23FFB800'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M101.499729,2.82302245e-05%20C102.285413,-0.00432461793%20103.254164,0.496634241%20103.645655,1.25173399%20L103.712109,1.39623206%20L105.747863,6.45331817%20L111.028779,6.80428588%20C111.60867,6.84282525%20112.147242,7.1236355%20112.517275,7.58038413%20C113.223405,8.45199453%20113.142035,9.72214747%20112.357105,10.4940033%20L112.234099,10.6059323%20L108.072656,14.10894%20L109.356339,19.592529%20C109.472157,20.0872738%20109.394126,20.6085551%20109.13883,21.0455786%20C108.624329,21.9263208%20107.536956,22.2447485%20106.649713,21.8010736%20L106.511398,21.7246573%20L101.5,18.7715858%20L96.4886024,21.7246573%20C95.5790916,22.2767096%2094.4027498,21.9726757%2093.8611695,21.0455786%20C93.6058745,20.6085551%2093.5278433,20.0872738%2093.6436608,19.592529%20L94.9273443,14.10894%20L90.7659013,10.6059323%20C89.8680707,9.85015912%2089.7412886,8.49557505%2090.4827254,7.58038413%20C90.8527577,7.1236355%2091.39133,6.84282525%2091.9712215,6.80428588%20L97.2521374,6.45331817%20L99.2878908,1.39623206%20C99.6240254,0.561228427%20100.665516,-0.00460395016%20101.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-7'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Was up 23.9% last month. Medtech has slumped for a while, but is rallying now as investors look for tech growth outside AI stocks. They reported a good quarter last week. Wished the PE were lower.